Horizon Pharma (HZNP) PT Raised to $39 at Cowen

Cowen analyst Ken Cacciatore raised the price target on Horizon Pharma (NASDAQ: HZNP) to $39.00 (from $35.00) while maintaining a Outperform rating.

The analyst commented, "Horizon's Q3 was nicely above, with the key outperformance all due to the more durable orphan portfolio, which now comprises 75% of total revenue. The primary driver was Krystexxa, which was up +42% Y/Y, and has clearly established itself as the backbone growth asset in the P&L. With Tepro set to provide meaningful P&L leverage & duration, the growth story is set to even further accelerate. Add."

You May Also Be Interested In

• RCM Technologies (RCMT) PT Raised to $45 at Benchmark on Q2 Beat
• Maxis Bhd (MAXIS:MK) (MAXSF) PT Raised to MYR3.82 at Nomura/Instinet
• LG Electronics India (LGEL:IN) PT Raised to INR1,983 at Nomura/Instinet